Towards a TDP-43-Based Biomarker for ALS and FTLD

@article{Feneberg2018TowardsAT,
  title={Towards a TDP-43-Based Biomarker for ALS and FTLD},
  author={Emily Feneberg and Elizabeth Gray and Olaf Ansorge and Kevin Talbot and Martin R. Turner},
  journal={Molecular Neurobiology},
  year={2018},
  volume={55},
  pages={7789 - 7801}
}
TDP-43 accumulates in nerve cells of nearly all cases of amyotrophic lateral sclerosis (ALS; the commonest form of motor neuron disease) and in the majority of Tau-negative frontotemporal lobar degeneration (FTLD). There is currently no biochemical test or marker of disease activity for ALS or FTLD, and the clinical diagnosis depends on the opinion of an experienced neurologist. TDP-43 has a key role in the pathogenesis of ALS/FTLD. Measuring TDP-43 in easily accessible biofluids, such as blood… 
Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia.
TLDR
The data uncovered truncated STMN2 as a marker for TDP-43 dysfunction in FTD, and observed significant associations of truncatedSTMN2 RNA with phosphorylated T DP-43 levels and an earlier age of disease onset.
Serum naturally occurring anti-TDP-43 auto-antibodies are increased in amyotrophic lateral sclerosis
TLDR
It is reported that serum anti-TDP-43 NAb are detectable in human serum of both healthy controls and patients affected by a variety of neurodegenerative disorders; furthermore, their levels are increased in ALS patients, representing a potentially interesting trait core marker of this disease.
Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies
TLDR
The development and validation of biomarkers that detect the pathological aggregates of TDP-43 in vivo are notably expected to further elucidate the pathophysiological underpinnings of extra-motor neurodegeneration in ALS.
TDP-43 Pathology in Alzheimer’s Disease
TLDR
The biology and pathobiology of TDP-43 are reviewed with a focus on its role in Alzheimer’s disease, highlighting the need for studies on the mechanisms that lead to T DP-43 pathology, especially in the setting of age-related disorders such as AD.
Fluid Biomarkers of Frontotemporal Lobar Degeneration.
TLDR
Novel techniques capable of measuring very low concentrations of brain-derived proteins in peripheral fluids are facilitating studies of blood biomarkers as a minimally invasive alternative to CSF.
Fluid biomarkers in frontotemporal dementia: past, present and future
TLDR
There is much still to learn in the fluid biomarker field in FTD, but the creation of large multinational cohorts is facilitating better powered studies and will pave the way for larger omics studies, including proteomics, metabolomics and lipidomics, as well as investigations of multimodal biomarker combinations across fluids, brain imaging and other domains.
TDP-43 Cytoplasmic Translocation in the Skin Fibroblasts of ALS Patients
TLDR
Significant increased TDP-43 levels in epidermis and in the cytoplasm of dermal cells of ALS patients are identified and provide support for the use of T DP-43 in skin biopsies as a potential biomarker for ALS.
Neurochemical biomarkers in amyotrophic lateral sclerosis.
TLDR
Neurofilaments seem to be ready for clinical use in the early and differential diagnosis of ALS, and two molecules have been extensively studied - the light chain and the phosphorylated form of the heavy chain of neurofilaments, NFL and pNFH, respectively - which have demonstrated a high diagnostic performance and promising prognostic value and are therefore ready to be introduced into the clinical scenario.
TDP-43 Is Elevated in Plasma Neuronal-Derived Exosomes of Patients With Alzheimer’s Disease
TLDR
This study demonstrated increased TDP-43 accumulation in AD patients by examining plasma NDEs, which may provide a window into the effects of T DP-43 on AD progression.
TDP-43 and Phosphorylated TDP-43 Levels in Paired Plasma and CSF Samples in Amyotrophic Lateral Sclerosis
TLDR
The plasma TDP-43 might differentiate ALS and HC groups based on high sensitivity and specificity, and as an indicator of progression of disease.
...
...

References

SHOWING 1-10 OF 112 REFERENCES
Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases
TLDR
Investigation of paired CSF and serum samples, blood lymphocytes, brain urea fractions and purified exosomes from CSF for TDP-43 by one- (1D) and two-dimensional (2D) Western immunoblotting and quantitative mass spectrometry in patients with ALS, FTLD and non-neurodegenerative diseases concludes that T DP-43 in CSF originates mainly from blood.
Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis
TLDR
Raised TDP-43 levels in the CSF may preempt the formation of T DP-43 pathology in the central nervous system, or correlate with early-stage TDP -43 pathology, and accordingly be a biomarker for the early stage of ALS.
Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study.
TLDR
It is concluded that with current available methods, CSF tau, rather than TDP-43 proteins, may have diagnostic value in the differentiation of FTLD patients with either tau or T DP-43 pathology.
TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
TLDR
CSF TDP-43 levels in CSF might aid in characterizing subgroups of patients across the ALS and FTLD disease spectrum, and although there is no evidence of pathologically altered Tarpa DNA-binding protein 43 proteins inCSF, TDP’s levels might aid the characterizing of patients within these subgroups.
TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies
TLDR
This systematic review provides an overview of antibodies that are reported to detect pathological TDP-43, with special interest in its modified isoforms, and selected antibodies hold the potential to be used in the development of novel immunoassays for the quantification of T DP-43 in biofluids, as a possible biomarker for FTLD-TDP.
TDP-43 proteinopathy: the neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease
TLDR
This review summarizes the growing evidence that TDP-43 proteinopathy is the common pathologic substrate linking FTLD and ALS, and it considers the implications for developing better strategies to diagnose and treat these neurodegenerative disorders.
Mass spectrometric analysis of accumulated TDP-43 in amyotrophic lateral sclerosis brains
TLDR
A highly sensitive liquid chromatography-mass spectrometry analysis of Sarkosyl-insoluble pathological TDP-43 from brains of ALS patients identified several novel phosphorylation sites, deamidation sites, and cleavage sites, suggesting that these sites may be more accessible to proteolytic enzymes.
TDP-43 protein variants as biomarkers in amyotrophic lateral sclerosis
TLDR
It is shown that a small panel of scFvs recognizing different TDP-43 variants can generate a neuropathological and plasma biomarker profile with potential to distinguish different T DP-43 pathologies.
Cerebrospinal Fluid TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis Patients with and without the C9ORF72 Hexanucleotide Expansion
TLDR
CSF TDP-43 does not seem to distinguish the C9ORF72 expansion carriers from noncarriers, however, higher CSF TPD-43 levels were detected in ALS than in FTLD, which might be an indicator of a more rapid progression of T DP-43 pathology in ALS.
...
...